| Literature DB >> 23711792 |
Francesca Pretto1, Dario Neri.
Abstract
Metastatic melanoma is one of the most deadly forms of cancer and is poorly responsive to standard chemotherapeutics, such as Dacarbazine and Paclitaxel. Recently, the advent of Vemurafenib and Ipilimumab has broadened the spectrum of therapeutic options for advanced melanoma patients but the occurrence of resistance and of high-grade toxicities call for better and more effective treatments. This review focuses on approved and experimental therapies for metastatic melanoma. The mechanism of action and the reported efficacy data for small molecule drugs and biologics are discussed, outlining directions for future pharmaceutical research in this field.Entities:
Keywords: CTLA-4; DTIC; EDB; ERK; GM-CSF; IFN-α; IL-2; IL2; Immunocytokines; Interferon-α; Interleukin-2; Ipilimumab; MAPK; MTD; Melanoma; PD-1R; PD-L1 and 2; PI3K; Vemurafenib; cytotoxic T-lymphocyte antigen 4; dacarbazine; extra-domain B of fibronectin; extracellular-signal-regulated kinases; granulocyte-macrophage colony-stimulating factor; maximum tolerated dose; mitogen-activated protein kinases; phosphatidylinositol 3-kinases; programmed cell death 1 ligand 1 and 2; programmed death-1 receptor
Mesh：
Substances：
Year: 2013 PMID： 23711792 DOI： 10.1016/j.pharmthera.2013.05.006
Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310